Matthew Young, Jazz Pharmaceuticals plc (JAZZ)’s insider Sold 1,420 Shares; Profile of 5 Analysts Covering SafeCharge International Group Limited (LON:SCH)

May 17, 2018 - By Clifton Ray

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Logo

Among 6 analysts covering Safecharge International Group (LON:SCH), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Safecharge International Group had 26 analyst reports since July 23, 2015 according to SRatingsIntel. The stock has “Buy” rating by Numis Securities on Thursday, February 4. Canaccord Genuity maintained it with “Buy” rating and GBX 320 target in Tuesday, June 7 report. Berenberg maintained SafeCharge International Group Limited (LON:SCH) on Thursday, February 9 with “Buy” rating. Canaccord Genuity maintained it with “Buy” rating and GBX 320 target in Tuesday, March 21 report. Canaccord Genuity maintained it with “Buy” rating and GBX 320 target in Wednesday, September 16 report. As per Wednesday, May 18, the company rating was maintained by Canaccord Genuity. The rating was maintained by Barclays Capital with “Equal-Weight” on Monday, October 9. The stock of SafeCharge International Group Limited (LON:SCH) earned “Buy” rating by Canaccord Genuity on Thursday, July 20. The rating was maintained by Numis Securities on Thursday, January 21 with “Buy”. The firm has “Buy” rating by Berenberg given on Wednesday, September 14. See SafeCharge International Group Limited (LON:SCH) latest ratings:

19/03/2018 Broker: Berenberg Rating: Buy Old Target: GBX 350.00 New Target: GBX 350.00 Maintain
15/03/2018 Broker: Berenberg Rating: Buy Old Target: GBX 350.00 New Target: GBX 350.00 Maintain
14/03/2018 Broker: Canaccord Genuity Rating: Buy New Target: GBX 380.00 Maintain
13/03/2018 Broker: Berenberg Rating: Buy Old Target: GBX 350.00 New Target: GBX 350.00 Maintain
03/01/2018 Broker: Bryan Garnier & Cie Rating: Buy New Target: GBX 354.00 Initiates Starts
28/11/2017 Broker: Canaccord Genuity Rating: Buy Old Target: GBX 320.00 New Target: GBX 320.00 Maintain

SafeCharge International Group Limited provides payments services, technologies, and risk management solutions for online and mobile businesses in Europe and internationally. The company has market cap of 500.86 million GBP. It offers payments solutions, including Cashier, an online checkout solution; mCashier, a mobile checkout solution; POS, a point-of-sale checkout product; card acquiring and issuing services; fraud prevention platform, a real-time risk-mitigation solution; and transaction management solution, a transaction processing hub that routes transactions throughout the payment process encompassing various channels of payments from online, mobile, and POS. It has a 21.42 P/E ratio. The firm also provides dashboard, which offers insights for the checkout and payments process; and data analytics that enables merchants to make decisions that affect their conversion optimization, as well as customizable business intelligence reports, which are available specific to its merchantÂ’s requirements to gain insights into information critical to their business.

The stock decreased 0.31% or GBX 1.05 during the last trading session, reaching GBX 338.45. About 52,288 shares traded. SafeCharge International Group Limited (LON:SCH) has 0.00% since May 17, 2017 and is . It has underperformed by 11.55% the S&P500.

Among 23 analysts covering Jazz Pharmaceuticals (NASDAQ:JAZZ), 19 have Buy rating, 0 Sell and 4 Hold. Therefore 83% are positive. Jazz Pharmaceuticals has $229 highest and $124 lowest target. $181.13’s average target is 12.34% above currents $161.24 stock price. Jazz Pharmaceuticals had 84 analyst reports since August 3, 2015 according to SRatingsIntel. The rating was maintained by Piper Jaffray with “Buy” on Thursday, April 12. The firm has “Buy” rating given on Tuesday, September 19 by BMO Capital Markets. FBR Capital maintained Jazz Pharmaceuticals plc (NASDAQ:JAZZ) rating on Thursday, May 10. FBR Capital has “Buy” rating and $211 target. On Friday, October 9 the stock rating was initiated by Mizuho with “Buy”. The stock of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) earned “Buy” rating by Mizuho on Wednesday, November 9. Stifel Nicolaus maintained the shares of JAZZ in report on Wednesday, February 24 with “Buy” rating. The firm has “Buy” rating given on Friday, July 14 by Piper Jaffray. Mizuho maintained Jazz Pharmaceuticals plc (NASDAQ:JAZZ) rating on Tuesday, December 5. Mizuho has “Hold” rating and $150.0 target. The stock has “Hold” rating by H.C. Wainwright on Friday, March 23. Morgan Stanley upgraded Jazz Pharmaceuticals plc (NASDAQ:JAZZ) on Monday, March 19 to “Overweight” rating.

Investors sentiment increased to 1.09 in 2017 Q4. Its up 0.06, from 1.03 in 2017Q3. It increased, as 30 investors sold Jazz Pharmaceuticals plc shares while 89 reduced holdings. 49 funds opened positions while 81 raised stakes. 52.98 million shares or 1.12% less from 53.58 million shares in 2017Q3 were reported. Hsbc Hldgs Public Lc has 0% invested in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) for 6,567 shares. Carroll Financial Associate Inc accumulated 0% or 11 shares. Cwm Limited Com accumulated 0% or 119 shares. Wellington Management Group Ltd Liability Partnership invested in 0% or 69,343 shares. Maverick Limited invested in 43,540 shares. Citigroup Inc holds 0% or 17,402 shares. Virginia Retirement Systems Et Al owns 122,500 shares or 0.19% of their US portfolio. Bb&T Secs Lc has 1,918 shares for 0% of their portfolio. Glob X Management Ltd has 0% invested in Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Fisher Asset Management Limited Liability reported 1,606 shares or 0% of all its holdings. Tiaa Cref Mgmt Ltd Liability invested in 0.09% or 982,030 shares. Endurant Capital Mngmt L P has 0.2% invested in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) for 4,950 shares. Royal Bancorporation Of Canada accumulated 226,664 shares or 0.01% of the stock. Rock Springs Cap Management L P holds 0.76% or 123,700 shares in its portfolio. 3,200 are owned by Clough Capital Limited Partnership.

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has market cap of $9.67 billion. The firm has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It has a 20.26 P/E ratio. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain.

Since December 11, 2017, it had 0 insider purchases, and 21 selling transactions for $4.95 million activity. WILSON KAREN J also sold $604,345 worth of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) shares. $106,512 worth of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) was sold by Young Matthew P. on Tuesday, January 16. Another trade for 200 shares valued at $27,830 was made by MILLER MICHAEL PATRICK on Monday, December 11. Shares for $84,030 were sold by Treacy Paul on Tuesday, March 6. COZADD BRUCE C had sold 1,000 shares worth $150,010. ENRIGHT PATRICK G also sold $1.26 million worth of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) shares.

The stock decreased 0.99% or $1.62 during the last trading session, reaching $161.24. About 572,890 shares traded or 21.83% up from the average. Jazz Pharmaceuticals plc (NASDAQ:JAZZ) has declined 0.32% since May 17, 2017 and is downtrending. It has underperformed by 11.87% the S&P500.

The EVP & CFO of Jazz Pharmaceuticals Plc and firm’s insider Matthew Young unloaded 1,420 shares of the ‘s company calculated based on the stock price per share of $164.6 for every share. Matthew Young’s shares have a value of nearly $233,789 U.S Dollars. In the last 30 days, he also unloaded 700 shares valued at $109,207 USD. The sale was revealed in a Form 4 submitted with the DC-based SEC on 16-05-2018, which is available for online access here. The probability of this deal remaining ignored is nil as it’s new, with Matthew Young now having 36,203 shares —- that is 0.06% of the Company’s total market capitalization.

Analysts await Jazz Pharmaceuticals plc (NASDAQ:JAZZ) to report earnings on August, 14. They expect $2.87 earnings per share, up 66.86% or $1.15 from last year’s $1.72 per share. JAZZ’s profit will be $172.19M for 14.05 P/E if the $2.87 EPS becomes a reality. After $2.63 actual earnings per share reported by Jazz Pharmaceuticals plc for the previous quarter, Wall Street now forecasts 9.13% EPS growth.

More notable recent Jazz Pharmaceuticals plc (NASDAQ:JAZZ) news were published by: Bizjournals.com which released: “Peninsula drug maker swings $110 million deal for voucher” on April 30, 2018, also Fool.com with their article: “3 Top Biotech Stocks to Buy in May” published on May 09, 2018, Seekingalpha.com published: “Jazz Pharmaceuticals Plc (JAZZ) Q1 2018 Results – Earnings Call Transcript” on May 09, 2018. More interesting news about Jazz Pharmaceuticals plc (NASDAQ:JAZZ) were released by: Prnewswire.com and their article: “Jazz Pharmaceuticals Announces Participation in Three Upcoming Investor Conferences” published on May 09, 2018 as well as Streetinsider.com‘s news article titled: “Viking Global’s 13F Shows New Stakes in Alibaba (BABA), BioMarin (BMRN) and Western Digital (WDC), Increase in ..” with publication date: May 15, 2018.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:


>